

Table SI. Clinical features of patients with PF and control subjects.

No.	Type	Age, years	Sex
1	PF	78	Female
2	PF	70	Male
3	PF	54	Female
4	PF	64	Female
5	PF	67	Female
6	PF	74	Male
7	PF	57	Male
8	PF	61	Female
9	PF	39	Female
10	PF	62	Male
11	PF	45	Female
12	PF	55	Female
13	Control	76	Female
14	Control	51	Male
15	Control	51	Female
16	Control	63	Female
17	Control	62	Male
18	Control	58	Female
19	Control	47	Male
20	Control	50	Female
21	Control	48	Female
22	Control	49	Male
23	Control	55	Male
24	Control	52	Female
25	Control	77	Male
26	Control	49	Male
27	Control	55	Female
28	Control	47	Female
29	Control	53	Female

PF, pulmonary fibrosis.

Table SII. Sequences of miR-483-5p mimic, inhibitor, RhoGDI1 and corresponding negative controls.

Name	Sequence, 5'→3'
hsa-miR-483-5p mimic	F: AAGACGGGAGGAAAGAAGGGAG R: CCCUUCUUUCCUCCCGUCUUUU
Mimic negative control	F: UUCUCCGAACGUGUCACGUTT R: ACGUGACACGUUCGGAGAATT
hsa-miR-483-5p inhibitor	CUCCCUUCUUUCCUCCCGUCUU
Inhibitor negative control	CAGUACUUUUGUGUAGUACAA
RhoGDI1	CCGCTTCACAGACGACGACAA
RhoGDI1 negative control	TTCTCCGAACGTGTCACGTAA

RhoGDI1, Rho GDP dissociation inhibitor 1; F, forward; R, reverse; miR, microRNA.

Table SIII. Forward and reverse primers for reverse transcription-quantitative PCR.

Gene	Direction	Sequence, 5'→-3'
miR-483-5p	Forward	AAGGAGAAGACGGGAGGAAAGA
	Reverse	GTGCAGGGTCCGAGGT
U6	Forward	CAGCACATATACTAAAATTGGAACG
	Reverse	ACGAATTTGCGTGTCATCC
E-cadherin	Forward	CGATTCAAAGTGGGCACAGATG
	Reverse	GTAGG TGGAGTCCCAGGCGTAG
Vimentin	Forward	TCTGGATTCACTCCCTCTGGTT
	Reverse	ATCGTGATGCTGAGAAGTTTCGT
α -SMA	Forward	ATGCTCCCAGGGCTGTTTTTC
	Reverse	CTTTTGCTCTGTGCTTCGTC
RhoGDI1	Forward	CGACGAGAGCCTGCGAAAGT
	Reverse	CACCCTCCTTCAGCACAAACG
GAPDH	Forward	CTTTGGTA TCGTGGAAGGACTC
	Reverse	GTAGAGGCAGGGATGATGTTCT

α -SMA, α -smooth muscle actin; RhoGDI1, Rho GDP dissociation inhibitor 1; miR, microRNA.